Strong progress in vaccine R&D, with secured financing and grants supporting clinical advancement of pneumococcal and influenza candidates. Q3 saw higher grant income but continued net losses, with a robust cash position and equity base.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.